Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

ents were randomized 1:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo. CAPACITY 2 enrolled a total of 435 patients, and patients were randomized 2:2:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo, or a total daily dose of 1197 mg pirfenidone, respectively, administered in three divided doses. The lower dose of pirfenidone in CAPACITY 2 provided safety and tolerability data. The pre-specified statistical analysis plan did not call for this low-dose group to be used in any analyses of efficacy. The pooled analyses of the primary and secondary efficacy outcome measures were based on a combined analysis of the 2403 mg group compared with the placebo group across both studies and were considered exploratory.

Enrollment of both trials was completed in less than 13 months following randomization of the first patient into the program in late April 2006. Ninety-seven percent (97%) of all patients in the two CAPACITY studies who were living and had not received a lung transplant, completed their Week 72 study visit.

Each trial in CAPACITY was designed to have greater than 95% statistical power to detect a 50% reduction in the rate of FVC progression compared to placebo after 72 weeks of treatment and greater than 85% statistical power to detect a 40% reduction after the same period, when compared to placebo. The pre-specified secondary endpoints of CAPACITY were:

        1.  Time to worsening of IPF, defined as time to acute IPF
            exacerbation, IPF-related death, lung transplant or respiratory
            hospitalization, whichever comes first
        2.  Progression-free survival defined as time to the first occurrence
            of either of the following (as compared to the patient's
            baseline):
              --  10% absolute decline in percent predicted FVC, or
              --  15% absolute decline in percent predicted Hb-corrected
        
'/>"/>
SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce ... V19 with PVM technology , is now available. ... measurement tool continuously captures high-resolution images under a ... automatically prepares a report pairing the most relevant ... changes. This compelling blend of high resolution images ...
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) ... as an independent director of the Company,s Board ... AeroScout and served as its CEO until its acquisition ... a $240 million transaction. Recognized as the inventor of ... leadership, AeroScout provided Wi-Fi -based RFID solutions focused on ...
(Date:12/13/2014)... December 13, 2014 CanDiag, Inc., a ... company has changed its name to OncoTab, Inc. ... of where we are today,” said CEO and Chief ... platform’s applications beyond breast cancer diagnostics to include imaging ... of that evolution.” , Founded in 2011 by Dr. ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... , , , ... Transcriptor Reverse Transcriptase in,the Eberwine Target Preparation Workflow , ... , , Reproducibility and sensitivity are key parameters ... microarray,platforms has shifted the focus to target preparation as a,critical step in microarray ...
... , , ... , , Over the past decade, many organisms ... of gene sequences are now ready,for functional analysis. Knowledge of tissues and cells,that ... , , , , ...
... , , ... Roche Applied Science now offers new larger pack sizes,of PCR-Grade Nucleotides. These larger pack ... , , , Single dNTPs , ... , Single dNTPs are now available in 500-mol pack sizes.,The Deoxynucleoside ...
Cached Biology Technology:Increased Sensitivity in Microarray Analysis 2Increased Sensitivity in Microarray Analysis 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 2The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 4The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 5The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 6PCR-Grade Nucleotides,Larger Pack Sizes Now Available 2
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... off on a sun-powered adventure this autumn when the Durham ... Challenge. Using nothing but solar power, the DUSC team ... of Australia to Adelaide in the south. The Durham ... in mid-August after taking part in endurance testing in the ...
... Milan, Italy, August 11, 2011 Memory is not a ... on different areas of the brain. Episodic memory, the ability ... is known to be vulnerable to brain damage involving the ... hippocampus occurs very early in life? In a case study ...
... Loligo bleekeri ) employ different reproductive strategies depending on their ... BMC Evolutionary Biology shows that the divergent mating ... different sperm sizes. Large male squid compete for females ... female has chosen her partner they mate in an above ...
Cached Biology News:Durham University solar car takes on World Solar Challenge 2When you can recite a poem but not remember who asked you to learn it a few days earlier 2
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... software for the microscopy market by ... components and peripherals with powerful archiving, ... intuitive interface simplifies workflow and speeds ... powerful features such as image stitching, ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
Biology Products: